Pfizer (PFE) Breaks $20/Share as Bernstein Highlights Potential 'Significant Shake-Up'
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.05 +1.65%
Rating Summary:
14 Buy, 18 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
14 Buy, 18 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Pfizer (NYSE: PFE) have surged more than 3% today (the most in more than a year) amid a number of analyst comments this morning. The stock last traded at $20.09.
Traders in Pfizer seem to be liking a research note from Bernstein this morning in which an analyst argues that Pfizer management could be taking a look at a "significant shake-up." Bernstein's Tim Anderson suggests that the company may be looking to spin off not only all four of its non-pharma units (Consumer Health, Nutritionals, Capsule Manufacturing and Animal Health), but possibly even its Established Products branch. Anderson points out that the non-pharma units currently generate about $10 billion in sales a year and that the Established Products unit could generate as much as $17 billion in sales annually as Lipitor and other products go off patent.
Bernstein maintains an Outperform rating and $23 price target on shares of Pfizer.
Elsewhere on the Street, a Soleil analyst suggested that the stock could push over a resistance level at $20 with several catalysts approaching: the execution of a recent strategy laid out by CEO Read (update on the Capsugel unit, potentially by the end of Q1) and likely data releases for its oral JAK-3.
On the bearish side of things, an analyst at Standpoint Research cut the stock from Buy to Hold this morning given recent upside in PFE shares.
Notably, shares of Pfizer have not traded over the $20 level since early-2008.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Pfizer.
Traders in Pfizer seem to be liking a research note from Bernstein this morning in which an analyst argues that Pfizer management could be taking a look at a "significant shake-up." Bernstein's Tim Anderson suggests that the company may be looking to spin off not only all four of its non-pharma units (Consumer Health, Nutritionals, Capsule Manufacturing and Animal Health), but possibly even its Established Products branch. Anderson points out that the non-pharma units currently generate about $10 billion in sales a year and that the Established Products unit could generate as much as $17 billion in sales annually as Lipitor and other products go off patent.
Bernstein maintains an Outperform rating and $23 price target on shares of Pfizer.
Elsewhere on the Street, a Soleil analyst suggested that the stock could push over a resistance level at $20 with several catalysts approaching: the execution of a recent strategy laid out by CEO Read (update on the Capsugel unit, potentially by the end of Q1) and likely data releases for its oral JAK-3.
On the bearish side of things, an analyst at Standpoint Research cut the stock from Buy to Hold this morning given recent upside in PFE shares.
Notably, shares of Pfizer have not traded over the $20 level since early-2008.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Pfizer.
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Soleil Securities, Standpoint ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
